{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:29:21Z","timestamp":1792441761768,"version":"4.5.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Life-prolonging targeted therapies are available based on alterations detected on next-generation sequencing (NGS); however, clinical data on NGS adoption are limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess trends and disparities in NGS among patients with common advanced or metastatic cancers.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Retrospective cohort study of 280 US-based cancer clinics (approximately 800 sites of care) using electronic health record\u2013derived deidentified information from Flatiron Health Research Database. Participants were patients diagnosed with metastatic breast (mBC), metastatic prostate (mPC), advanced non\u2013small cell lung (aNSCLC), metastatic colorectal (mCRC), and metastatic pancreatic (mPanC) cancers between January 1, 2018, and December 30, 2022. Data were analyzed from April 2024 to December 2025.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Time to NGS from diagnosis, considering death as competing risk. Multivariable cause-specific Weibull accelerated failure time models evaluated association of socioeconomic status (SES), race and ethnicity, insurance type, practice setting, and sex with time to NGS.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Overall, 63\u202f294 patients with advanced or metastatic cancer were eligible and included: 12\u202f085 with mBC (19.1%), 4341 with mPC (6.9%), 27\u202f050 with aNSCLC (42.7%), 13\u202f648 with mCRC (21.6%), and 6170 with mPanC (9.7%). The median (IQR) age was 68 (60-76) years and 33\u202f975 patients (53.7%) were female; 1703 (2.7%) were Asian, 6551 (10.0%) were Black, 3772 (6.0%) were Hispanic, 38\u202f318 (61.0%) were White, and 12\u202f950 (20.3%) were other races and ethnicities. One-year cumulative incidence of NGS increased in patients diagnosed in 2022 compared with 2018 across all cancer types. Significantly longer time to NGS (time ratio [TR]) was observed in those with mBC with low SES (1, lowest: TR, 1.3; 95% CI, 1.1-1.6; 2: TR, 1.3; 95% CI, 1.1-1.5), those who were Hispanic (TR, 1.4; 95% CI, 1.2-1.7), or those on Medicare (TR, 1.5; 95% CI, 1.3-1.8). Longer TRs were also observed in those with mPC and Hispanic ethnicity (TR, 1.6; 95% CI, 1.3-2.1), those on Medicaid (TR, 2.0; 95% CI, 1.2-3.5), those with aNSCLC with low SES (1, lowest: TR, 1.6; 95% CI, 1.5-1.8; 2: TR, 1.4; 95% CI, 1.3-1.6; 3: TR, 1.2; 95% CI, 1.1-1.3), Black patients (TR, 1.4; 95% CI, 1.2-1.5), and those on Medicare (TR, 1.4; 95% CI, 1.3-1.5). For mCRC, TRs were elevated for those with low SES (1, lowest: TR, 1.3; 95% CI, 1.1-1.5; 2: TR, 1.1; 95% CI, 1.0-1.3), Black patients (TR, 1.4; 95% CI, 1.2-1.6), Hispanic patients (TR, 1.4; 95% CI, 1.2-1.6), and those on Medicare (TR, 1.4; 95% CI, 1.3-1.6). Elevated TRs were also observed for mPanC in Black patients (TR, 1.5; 95% CI, 1.2-1.8) and those on Medicare (TR, 1.3; 95% CI, 1.1-1.5).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, many patients with advanced or metastatic cancers did not undergo tumor genomic testing. Low SES, Black race or Hispanic ethnicity, and Medicaid or Medicare coverage were associated with significantly longer time to NGS, highlighting the need for awareness and health care policies aimed at bridging these gaps.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.5585","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T15:00:21Z","timestamp":1775574021000},"page":"e265585","source":"Crossref","is-referenced-by-count":7,"title":["Trends and Disparities in the Use of Next-Generation Sequencing in Patients With Cancer in the United States"],"prefix":"10.1001","volume":"9","author":[{"given":"Chadi","family":"Hage Chehade","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep Irem","family":"Ozay","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonjung","family":"Jo","sequence":"additional","affiliation":[{"name":"Cancer Biostatistics, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Gebrael","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Sayegh","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"},{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micah","family":"Ostrowski","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayana","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diya","family":"Garg","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanner","family":"Hardy","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan G.","family":"Murdock","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshit","family":"Narang","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Mathew Thomas","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, University of Kansas Cancer Center, Westwood"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin L.","family":"Maughan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumyajit","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umang","family":"Swami","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"issue":"5","key":"zoi260199r1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000094","article-title":"Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls.","volume":"1","author":"Horak","year":"2016","journal-title":"ESMO Open"},{"issue":"1","key":"zoi260199r2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/cas.13837","article-title":"Next generation sequencing-based gene panel tests for the management of solid tumors.","volume":"110","author":"Nagahashi","year":"2019","journal-title":"Cancer Sci"},{"issue":"4","key":"zoi260199r3","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s41591-022-01717-2","article-title":"Delivering precision oncology to patients with cancer.","volume":"28","author":"Mateo","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"zoi260199r4","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s12253-016-0124-z","article-title":"Clinical applications of next-generation sequencing in cancer diagnosis.","volume":"23","author":"Sabour","year":"2017","journal-title":"Pathol Oncol Res"},{"issue":"3","key":"zoi260199r5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1001\/jamaoncol.2016.5299","article-title":"Novel precision medicine trial designs: umbrellas and baskets.","volume":"3","author":"West","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi260199r6","first-page":"12","article-title":"Cancer statistics, 2024.","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"zoi260199r7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00169","article-title":"Use of next-generation sequencing tests to guide cancer treatment: results from a nationally representative survey of oncologists in the United States.","volume":"2","author":"Freedman","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"zoi260199r8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3322\/caac.21870","article-title":"A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors.","volume":"75","author":"Hage Chehade","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"zoi260199r9","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200043","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"issue":"18","key":"zoi260199r10","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1200\/JCO.23.00638","article-title":"Testing for ESR1 mutations to guide therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline rapid recommendation update.","volume":"41","author":"Burstein","year":"2023","journal-title":"J Clin Oncol"},{"issue":"20","key":"zoi260199r11","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer.","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi260199r12","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation.","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"zoi260199r13","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer.","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi260199r14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"zoi260199r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103561","article-title":"The storm of NGS in NSCLC diagnostic-therapeutic pathway: how to sun the real clinical practice.","volume":"169","author":"De Maglio","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"zoi260199r16","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.annonc.2024.07.730","article-title":"The ESMO tumour-agnostic classifier and screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development.","volume":"35","author":"Westphalen","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"zoi260199r17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jmoldx.2024.01.005","article-title":"Next-generation sequencing trends among adult patients with select advanced tumor types: a real-world evidence evaluation.","volume":"26","author":"Ferreira-Gonzalez","year":"2024","journal-title":"J Mol Diagn"},{"issue":"7","key":"zoi260199r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.23186","article-title":"Trends and disparities in next-generation sequencing in metastatic prostate and urothelial cancers.","volume":"7","author":"Hage Chehade","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi260199r19","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1245\/s10434-024-16464-6","article-title":"Disparities in next-generation genetic sequencing among individuals with cancer.","volume":"32","author":"Khan","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"zoi260199r20","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1158\/2767-9764.CRC-24-0134","article-title":"Association of race and ethnicity with genomic testing at a comprehensive cancer center in North Carolina.","volume":"4","author":"Meernik","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"8","key":"zoi260199r22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1023\/A:1011240019516","article-title":"Socioeconomic status and breast cancer incidence in California for different race\/ethnic groups.","volume":"12","author":"Yost","year":"2001","journal-title":"Cancer Causes Control"},{"key":"zoi260199r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.sste.2021.100412","article-title":"A comparison of two neighborhood-level socioeconomic indexes in the United States.","volume":"37","author":"Boscoe","year":"2021","journal-title":"Spat Spatiotemporal Epidemiol"},{"issue":"2","key":"zoi260199r25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer.","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"10502","key":"zoi260199r26","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(25)00683-X","article-title":"Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.","volume":"406","author":"Fizazi","year":"2025","journal-title":"Lancet"},{"key":"zoi260199r27","doi-asserted-by":"publisher","DOI":"10.1200\/GO-24-00416","author":"Horgan","year":"2025","journal-title":"JCO Glob Oncol"},{"key":"zoi260199r28","first-page":"167","article-title":"Health disparities: gaps in access, quality and affordability of medical care.","volume":"123","author":"Riley","year":"2012","journal-title":"Trans Am Clin Climatol Assoc"},{"issue":"1","key":"zoi260199r29","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1080\/13696998.2024.2314430","article-title":"Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer.","volume":"27","author":"Bestvina","year":"2024","journal-title":"J Med Econ"},{"issue":"12","key":"zoi260199r31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.38219","article-title":"Trends in use of next-generation sequencing in patients with solid tumors by race and ethnicity after implementation of the Medicare national coverage determination.","volume":"4","author":"Sheinson","year":"2021","journal-title":"JAMA Netw Open"},{"key":"zoi260199r21","unstructured":"Flatiron Health. Database characterization guide. Accessed April 21, 2025. https:\/\/flatiron.com\/database-characterization"},{"key":"zoi260199r24","unstructured":"Davis CE, Hyde JE, Bangdiwala SI, Nelson JJ. An example of dependencies among variables in a conditional logistic regression. 1986. Accessed January 13, 2026. https:\/\/www.scienceopen.com\/document?vid=0b246de8-95d4-4078-b870-33be78ef28cd"},{"key":"zoi260199r30","unstructured":"Centers for Medicare and Medicaid Services. NCD\u2014next generation sequencing (NGS). 2020. Accessed November 1, 2023. https:\/\/www.cms.gov\/medicare-coverage-database\/view\/ncd.aspx?NCDId=372"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2847397\/hage_chehade_2026_oi_260199_1777921865.43053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:00:24Z","timestamp":1778166024000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2847397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.5585","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]}}}